Dr Roshan Lal Aggarwal And Sons Profile
Key Indicators
- Authorised Capital ₹ 1.20 M
as on 24-10-2024
- Paid Up Capital ₹ 1.20 M
as on 24-10-2024
- Company Age 37 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 0.64%
(FY 2023)
- Profit 46.00%
(FY 2023)
- Ebitda 41.67%
(FY 2023)
- Net Worth 25.46%
(FY 2023)
- Total Assets 22.84%
(FY 2023)
About Dr Roshan Lal Aggarwal And Sons
The Company is engaged in the E-Commerce Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.20 M and a paid-up capital of Rs 1.20 M, as per Ministry of Corporate Affairs (MCA) records.
Subash Gupta, Poonam Gupta, and Nitin Gupta serve as directors at the Company.
- CIN/LLPIN
U74899DL1987PTC027876
- Company No.
027876
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 May 1987
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Dr Roshan Lal Aggarwal And Sons Private Ltd offer?
Dr Roshan Lal Aggarwal And Sons Private Ltd offers a wide range of products and services, including Homeopathic Medicines & Remedies, Homeopathic Drugs.
Who are the key members and board of directors at Dr Roshan Lal Aggarwal And Sons?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subash Gupta  | Director | 07-May-1987 | Current |
| Poonam Gupta | Director | 08-May-1987 | Current |
| Nitin Gupta | Director | 01-Apr-1997 | Current |
Financial Performance and Corporate Structure Insights of Dr Roshan Lal Aggarwal And Sons.
Dr Roshan Lal Aggarwal And Sons Private Ltd, for the financial year ended 2023, experienced modest growth in revenue, with a 0.64% increase. The company also saw a substantial improvement in profitability, with a 46% increase in profit. The company's net worth Soared by an impressive increase of 25.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr Roshan Lal Aggarwal And Sons?
In 2023, Dr Roshan Lal Aggarwal And Sons had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dr.Reckeweg Roshanlal (India) Private LimitedActive 19 years 3 monthsSubash Gupta and Nitin Gupta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dr Roshan Lal Aggarwal And Sons?
Dr Roshan Lal Aggarwal And Sons has a workforce of 176 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr Roshan Lal Aggarwal And Sons, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr Roshan Lal Aggarwal And Sons's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
